PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15136366-0	2004	Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes.	rofecoxib	0-9	interleukin 6	Homo sapiens	60-73	
15136366-2	2004	AIM: To evaluate whether patients with ACS treated with rofecoxib, a COX-2 inhibitor, will have reduced CRP, IL-6, and soluble tumor necrotic factor receptor-1 (sTNF-R1) levels and improved endothelial function.	rofecoxib	56-65	interleukin 6	Homo sapiens	109-113	
15136366-6	2004	IL-6 levels were significantly lower at 1 month (p < 0.02) in the rofecoxib group, but not at 3 months.	rofecoxib	69-78	interleukin 6	Homo sapiens	0-4	
15136366-8	2004	CONCLUSION: Patients recovering from ACS had lower levels of CRP and IL-6 at 1 month and lower CRP levels at 3 months when treated with rofecoxib plus aspirin.	rofecoxib	136-145	interleukin 6	Homo sapiens	69-73